



19 September 2025

Two New Patents Strengthen BLIS Global IP Position

BLIS Technologies (NZX: BLT) is pleased to announce that two new patents have been granted by the Australian Patent Office, further strengthening BLIS' leadership in oral probiotics and supporting its growth strategy in global health markets.

The patents cover:

- Antiviral Applications: Protects the use of Streptococcus salivarius K12 and M18 for defending against key upper respiratory viruses including SARS-CoV-2, Influenza A & B, and RSV.
- Enhanced Formulations: Secures proprietary combinations of *Streptococcus salivarius* K12 and M18 with specific prebiotic sugars proven to enhance antimicrobial activity.

What this means for BLIS:

- Growth: Enables development of new products in high-value global health markets.
- Innovation: Validates BLIS' R&D leadership and investment in science-backed technologies.
- Market Leadership: Strengthens BLIS' competitive edge and supports long-term global IP strategy.

"These patents cement BLIS' position as a global leader in oral probiotics, unlocking new product opportunities and protecting our science-backed innovation pipeline for long-term growth," says CEO Scott Johnson.

Ends

For further information, please contact:

Scott Johnson Chief Executive Officer +64 21 488 831

About BLIS Technologies Ltd

Delivering proven health benefits through evidence-based, advanced probiotics

BLIS Technologies is an NZX-listed manufacturer of advanced probiotic strains that go beyond the gut. Combining innovation with evidence-based research and the highest quality production controls enables the delivery of probiotic solutions for specific health targets including throat health, halitosis (bad breath), immune support, teeth and gum health and skin health. BLIS® products are sold throughout New Zealand and in Asia, Europe and the USA. More information about BLIS Technologies Ltd can be found at www.blis.co.nz.

Website: www.blis.co.nz

Instagram: @blisprobiotics #blisk12 #blism18 #blisq24

Facebook: @BLISProbiotics